Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Sep 15.
doi: 10.1038/s41569-025-01195-2. Online ahead of print.

Arrhythmia-induced cardiomyopathy: focus on atrial fibrillation

Affiliations
Review

Arrhythmia-induced cardiomyopathy: focus on atrial fibrillation

Larissa Fabritz et al. Nat Rev Cardiol. .

Abstract

Arrhythmias and heart failure (HF) are common causes of morbidity and premature death worldwide, and patients who present with both conditions have particularly poor outcomes. Arrhythmia-induced cardiomyopathy (AIC) is a condition in which arrhythmias, often atrial fibrillation (AF), but also frequent atrial or ventricular ectopic beats, cause or aggravate HF. The hallmark of this condition is partial or complete reversibility of left ventricular systolic dysfunction after restoration of normal sinus rhythm. Differentiation between HF that causes arrhythmias and arrhythmias that cause HF remains challenging, leads to the underuse of rhythm-control therapy and, consequently, to the under-diagnosis of AIC. In this Review, we describe the various pathophysiological mechanisms of AIC, with a focus on AF as the underlying arrhythmia. We then discuss the epidemiology, clinical presentation and assessment of patients with AIC, with consideration of the complex interactions between AF and left ventricular dysfunction. We also present the therapeutic approach taken in patients presenting with suspected AIC, including restoration of sinus rhythm to unmask a diagnosis of AIC and treatment of HF. We conclude with a discussion of priorities for future research and the observation that there is an urgent need for objective, easily quantifiable parameters to identify patients with AIC.

PubMed Disclaimer

Conflict of interest statement

Competing interests: L.F. has received institutional research grants and non-financial support from the British Heart Foundation, Daiichi–Sankyo, Deutsche Forschungsgemeinschaft, the European Union, German Center for Cardiovascular Research supported by the German Ministry of Education and Research DZHK, Medical Research Council, the National Institute for Health and Care Research, Roche and Preventicus; and is listed as the inventor on two patents held by the University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). The Institute of Cardiovascular Research, University of Birmingham, has received an Accelerator Award from the British Heart Foundation. S.S. has received a scientific grant from Novartis and speaker’s/consultancy honoraria from AstraZeneca, Berlin-Chemie and Boehringer Ingelheim Pharma. S.N.H. declares no competing interests.

References

    1. Vinter, N. et al. Temporal trends in lifetime risks of atrial fibrillation and its complications between 2000 and 2022: Danish, nationwide, population based cohort study. BMJ 385, e077209 (2024). - PubMed - PMC - DOI
    1. McDonagh, T. A. et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42, 3599–3726 (2021). - PubMed - DOI
    1. Hindricks, G. et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 42, 373–498 (2021). - PubMed - DOI
    1. Staerk, L. et al. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. BMJ 361, k1453 (2018). - PubMed - PMC - DOI
    1. Magnussen, C. et al. Sex differences and similarities in atrial fibrillation epidemiology, risk factors, and mortality in community cohorts: results from the BiomarCaRE consortium (biomarker for cardiovascular risk assessment in Europe). Circulation 136, 1588–1597 (2017). - PubMed - PMC - DOI

LinkOut - more resources